Background: Psychiatric disorders are frequent in dermatology patients, and many studies pointed out complex, mutual relationships between psyche and skin. Our aim was to provide a systematic psychosocial evaluation of a large and heterogeneous population of patients with skin diseases, including assessments of quality of life, psychiatric status according to the DSM-IV and psychological conditions with psychosomatic relevance according to established criteria (Diagnostic Criteria for Psychosomatic Research, DCPR). Methods: We studied 545 dermatological inpatients aged 18–65 years, free from dementia and cognitive impairment. They completed the Skindex-29 and the 12-item General Health Questionnaire (GHQ-12) and were administered the SCID-I and the Structured Interview for Psychological Conditions of Psychosomatic Relevance by a trained mental health professional blinded to questionnaire scores. Results: Overall, 38% of patients received a DSM-IV diagnosis. The most common diagnoses were mood (20%) and anxiety disorders (16%); 48% of patients also received a DCPR diagnosis. The most common were demoralisation, irritable mood, type A behaviour and various forms of abnormal illness behaviour. Adjusting for gender, age, and education, the presence of DSM-IV or DCPR diagnoses was significantly associated with high scores on the GHQ-12 and on the Functioning and Emotions scales of the Skindex-29. Also, DCPR diagnoses were significantly associated with high scores on the Symptoms scale of the Skindex-29. Conclusions: These findings highlight the high frequency of psychosocial problems in patients with skin disease and suggest that the joint use of DSM-IV and DCPR criteria may help identify those patients in whom psychiatric issues are worthy of increased clinical attention.

Keywords:
Skin disease, Quality of life, Depression, Anxiety, DCPR
1.
Hughes JE, Barraclough BM, Hamblin LG, White GE: Psychiatric symptoms in dermatology patients. Br J Psychiatry 1983;143:51–54.
2.
Wessely SC, Lewis GH: The classification of psychiatric morbidity in attenders at a dermatology clinic. Br J Psychiatry 1989;155:686–691.
3.
Aktan S, Ozmen E, Sanli B: Psychiatric disorders in patients attending a dermatology outpatient clinic. Dermatology 1998;197:230–234.
4.
Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P: Psychiatric morbidity in dermatological outpatients: An issue to be recognized. Br J Dermatol 2000;143:983–991.
5.
Niemeier V, Harth W, Kupfer J, Mayer K, Linse R, Schill WB, Gieler U: Prevalence of psychosomatic disorders in dermatologic patients. Experiences in 2 dermatology clinics with a liaison therapy model (in German). Hautarzt 2002;53:471–477.
6.
Gupta MA, Gupta AK: Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846–850.
7.
Colón EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK: Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 1991;32:245–251.
8.
Koblentzer CS: Psychosomatic concepts in dermatology. Arch Dermatol 1983;119:501–512.
9.
Van Moffaert M: Psychodermatology: An overview. Psychother Psychosom 1992;58:125–136.
10.
Picardi A, Abeni D: Stressful life events and skin diseases: Disentangling evidence from myth. Psychother Psychosom 2001;70:118–136.
11.
Schneider G, Gieler U: Psychosomatic dermatology – state of the art (in German). Z Psychosom Med Psychother 2001;47:307–331.
12.
Picardi A, Abeni D, Renzi C, Braga M, Melchi CF, Pasquini P: Treatment outcome and incidence of psychiatric disorders in dermatological outpatients. J Eur Acad Dermatol Venereol 2003;17:155–159.
13.
Regier DA, Boyd JH, Burke Jr JD, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ: One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988;45:977–986.
14.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
15.
Fortune DG, Richards HL, Griffiths CE, Main CJ: Psychological stress, distress and disability in patients with psoriasis: Consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 2002;41:157–174.
16.
Fava GA, Freyberger H, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995;63:1–8.
17.
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ: Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133:1433–1440.
18.
Jones-Caballero M, Penas PF, Garcia-Diez A, Badia X, Chren MM: The Spanish version of Skindex-29. Int J Dermatol 2000;39:907–912.
19.
Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM: Further evidence of the validity and reliability of Skindex-29: An Italian study on 2,242 outpatients. Dermatology 2002;204:43–49.
20.
Goldberg DP: The detection of psychiatric illness by questionnaire. London, Oxford University Press, 1972.
21.
Piccinelli M, Bisoffi G, Bon MG, Cunico L, Tansella M: Validity and test-retest reliability of the Italian version of the 12-item General Health Questionnaire in general practice: A comparison between three scoring methods. Compr Psychiatry 1993;34:198–205.
22.
Picardi A, Abeni D, Pasquini P: Measuring psychological distress in patients with skin disease: Validity, reliability and factor structure of the GHQ-12. J Eur Acad Dermatol Venereol 2001;15:410–417.
23.
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-I CV). Italian version by Mazzi F, Morosini P, de Girolamo G, Lussetti M, Guaraldi GP. Florence, Organizzazioni Speciali, 2000.
24.
Fava GA, Mangelli L, Ruini C: Assessment of psychological distress in the setting of medical disease. Psychother Psychosom 2001;70:171–175.
25.
Mangelli L, Rafanelli C, Porcelli P, Fava GA: Interview for the Diagnostic Criteria for Psychosomatic Research (DCPR). Psychother Psychosom 2003;72:346–348
26.
Galeazzi GM, Ferrari S, Mackinnon A, Rigatelli M: Interrater reliability, prevalence, and relation to ICD-10 diagnoses of the Diagnostic Criteria for Psychosomatic Research in consultation-liaison psychiatry patients. Psychosomatics 2004;45:386–393.
27.
Dean AG, Dean JA, Burton AH, Dicker RC: Epi Info: A general purpose microcomputer program for health information systems. Am J Prev Med 1991;7:178–182.
28.
Norusis MJ: SPSS for windows professional and advanced statistics, release 8.0. Chicago, SPSS Inc., 1998.
29.
Renzi C, Picardi A, Abeni D, Agostini E, Baliva G, Pasquini P, Puddu P, Braga M: Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002;138:337–342.
30.
Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N: Assessing demoralization and depression in the setting of medical disease. J Clin Psychiatry 2005;66:391–394.
31.
Wu SF, Kinder BN, Trunnell TN, Fulton JE: Role of anxiety and anger in acne patients: A relationship with the severity of the disorder. J Am Acad Dermatol 1988;18:325–333.
32.
Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y, Duncanson C, Shalita A: Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995;34:101–105.
33.
Ginsburg IH, Prystowsky JH, Kornfeld DS, Wolland H: Role of emotional factors in adults with atopic dermatitis. Int J Dermatol 1993;32:656–660.
34.
Clarke P, Ebel C, Catotti DN, Stewart S: The psychosocial impact of human papillomavirus infection: Implications for health care providers. Int J STD AIDS 1996;7:197–200.
35.
Fava GA, Grandi S, Savron G, Bartolucci G, Santarsiero G, Trombini G, Orlandi C: Psychosomatic assessment of hirsute women. Psychother Psychosom 1989;51:96–100.
36.
White A, Horne DJ, Varigos GA: Psychological profile of the atopic eczema patient. Australas J Dermatol 1990;31:13–16.
37.
Niemeier V, Fritz J, Kupfer J, Gieler U: Aggressive verbal behaviour as a function of experimentally induced anger in persons with psoriasis. Eur J Dermatol 1999;9:555–558.
38.
Gupta MA, Gupta AK, Watteel GN: Early onset (<40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: A study of 137 patients. Acta Derm Venereol 1996;76:464–466.
39.
Bankier B, Littman AB: Psychiatric disorder and coronary heart disease in women. Psychother Psychosom 2002;71:133–140.
40.
Rafanelli C, Roncuzzi R, Finos L, Tossani E, Tomba E, Mangelli L, Urbinati S, Pinelli G, Fava GA: Psychosocial assessment in cardiac rehabilitation. Psychother Psychosom 2003;72:343–349.
41.
Porcelli P, De Carne M, Fava GA: Assessing somatization in functional gastrointestinal disorders. Psychother Psychosom 2000;69:198–204.
42.
Pilowsky F: Abnormal illness behaviour. Psychother Psychosom 1986;46:76–84.
43.
Sonino N, Navarrini C, Ruini C, Ottolini F, Paoletta A, Fallo F, Boscaro M, Fava GA: Persistent psychological distress in patients treated for endocrine disease. Psychother Psychosom 2004;73:78–83.
44.
Sobrinho LG: Psychopathology in endocrine disorders: Why so persistent after the cure? Psychother Psychosom 2004;73:65–67.
45.
Fava GA, Ruini C, Rafanelli C: Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 2004;73:145–148.
46.
Bech P: Modern psychometrics in clinimetrics. Psychother Psychosom 2004;73:134–138.
47.
Faravelli C: Assessment of psychopathology. Psychother Psychosom 2004;73:139–141.
48.
Nierenberg AA, Sonino N: From clinical observation to clinimetrics. Psychother Psychosom 2004;73:131–133.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.